Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• Lexicon Pharmaceuticals' (LXRX) stock has been reaffirmed with a "Sell (D-)" rating by Weiss Ratings, indicating concerns about its performance.
• Despite the negative outlook from Weiss Ratings, some analysts like HC Wainwright and Citigroup have given the stock a "Buy" rating with price targets of $4.00 and $1.90 respectively.
• Lexicon Pharmaceuticals recently reported an earnings beat with $0.01 EPS against a consensus estimate of ($0.08), showcasing potential despite its challenges.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also weighed in on the company. HC Wainwright restated a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Citigroup upped their price target on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the company a "buy" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded Lexicon Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $3.23.

Lexicon Pharmaceuticals Trading Down 5.9%

Shares of LXRX stock opened at $1.43 on Wednesday. The firm has a market capitalization of $519.66 million, a P/E ratio of -4.33 and a beta of 1.23. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.18. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.43. The stock's fifty day simple moving average is $1.19 and its 200 day simple moving average is $0.89.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $28.87 million for the quarter, compared to analyst estimates of $4.87 million. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%. As a group, sell-side analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Hudson Bay Capital Management LP bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $26,000. R Squared Ltd bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at about $28,000. Straight Path Wealth Management bought a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at about $29,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter valued at about $32,000. Finally, CWM LLC boosted its position in shares of Lexicon Pharmaceuticals by 9,228.4% during the 1st quarter. CWM LLC now owns 105,504 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 104,373 shares in the last quarter. Institutional investors own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.